Encephalitis clinical trials at UC Irvine

1 in progress, 0 open to eligible people

Showing trials for

  • The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis

    Sorry, not currently recruiting here

    Determine the difference in the modified Rankin score at 16 weeks in participants with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line" immunomodulatory therapies provided as standard-of-care, and either inebilizumab (investigational agent) or placebo.

    Orange, California and other locations

Our lead scientists for Encephalitis research studies include .

Last updated: